Search

Bristol-Myers Squibb Co.

Atidarymo kaina

SektoriusSveikatos priežiūra

63.7 -0.59

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

63.12

Max

64.41

Pagrindiniai rodikliai

By Trading Economics

Pajamos

638M

3.3B

Pardavimai

1.5B

13B

P/E

Sektoriaus vid.

14.718

56.597

Pelnas, tenkantis vienai akcijai

2.04

Dividendų pajamingumas

3.69

Pelno marža

25.561

Darbuotojai

32,500

EBITDA

1.3B

4.9B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+4.26% upside

Dividendai

By Acuity

Dividendų pajamingumas

Sektoriaus vid.

3.69%

2.18%

Kitas uždarbis

2026-10-29

Kita Ex Dividend data

2026-10-02

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

8.7B

136B

Ankstesnė atidarymo kaina

64.29

Ankstesnė uždarymo kaina

63.7

Naujienos nuotaikos

By Acuity

37%

63%

73 / 339 reitingas Healthcare

Bristol-Myers Squibb Co. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-14 19:26; UTC

Correlated Moves

Advancing amid favorable market conditions, State Street Health Care ETF rises.

2026-09-10 19:16; UTC

News

Bristol-Myers Squibb shares are lower as HSBC raises price target to $65.00 while maintaining a Hold rating amid ongoing market sentiment.

2026-09-09 23:01; UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, marking a potential rebound after three sessions of declines. No specific news was identified.

2026-09-08 23:06; UTC

Event

Bristol-Myers Squibb Co reported positive Phase 2 trial results for arlocabtagene autoleucel, contributing to shares advancing in after-market trading.

2026-09-04 22:14; UTC

Correlated Moves
Social Media

Bristol-Myers Squibb Co shares are lower in after-market trading following the FDA's withdrawal of Krazati's accelerated approval for colorectal cancer.

2026-09-03 21:51; UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, declining since Thursday's close amid a broader market rally and no specific company news.

2026-09-02 23:01; UTC

Bristol-Myers Squibb Co shares are lower in after-market hours. Broader market sentiment is affected by rising oil prices amid U.S.-Iran tensions.

2026-09-01 23:06; UTC

Correlated Moves

Bristol-Myers Squibb shares declined after market close, mirroring a broader downturn in the pharmaceutical sector amid rising oil prices and inflation concerns.

2026-08-31 20:07; UTC

News
Social Media
Correlated Moves
Event

Bristol-Myers Squibb shares are higher following positive long-term data on Camzyos presented at the European Society of Cardiology Congress, showing significant patient improvements.

2026-08-28 23:01; UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, rebounding from three consecutive lower sessions with no specific news identified.

2026-08-27 19:36; UTC

Bristol-Myers Squibb shares are lower today amid broader market concerns over rising inflation and potential Federal Reserve interest rate hikes.

2026-08-26 23:16; UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news identified to explain the decline following a routine session.

2026-08-25 23:21; UTC

Correlated Moves

Bristol-Myers Squibb Co shares are lower in after-market trading, influenced by a decline in the pharmaceutical sector and falling crude oil prices.

2026-08-24 23:41; UTC

Bristol-Myers Squibb shares are trading lower in after-market hours amid weak market conditions and heightened geopolitical tensions affecting overall investor sentiment.

2026-08-21 20:02; UTC

Social Media

Bristol-Myers Squibb Co is higher today following reports of a collaboration with Chai on antibody discovery, enhancing its drug development capabilities.

2026-08-20 20:01; UTC

News

Bristol-Myers Squibb shares are lower amid a significant decline in the Pharmaceuticals sub-sector, despite recent FDA approval for its multiple myeloma drug.

2026-08-19 23:21; UTC

Bristol-Myers Squibb Co shares are higher in after-market hours, fluctuating between a low of -0.28% and a high of 0.50% since Wednesday's close.

2026-08-18 19:46; UTC

Social Media

Bristol-Myers Squibb is using AI tools to cut clinical trial development times, trading higher amid positive market sentiment surrounding these advancements.

2026-08-17 23:01; UTC

Bristol-Myers Squibb Co shares are lower in after-market trading amid broader market concerns and unusual selling pressure, though no specific news was identified.

2026-08-14 20:06; UTC

Social Media
News
Event

Bristol-Myers Squibb shares are lower after FDA approval of Zenbexus due to concerns over its $29,500 pricing, which may dampen market sentiment.

2026-08-13 23:56; UTC

News
Event

Bristol-Myers Squibb's shares are lower after FDA approval of ZENBEXUS for multiple myeloma, amid concerns over drug risks and ongoing trial verification.

2026-08-12 23:56; UTC

Bristol-Myers Squibb Co shares rose in after-market trading following U.S. Consumer Price Index data, easing concerns about aggressive Federal Reserve interest rate hikes.

2026-08-11 23:01; UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, rising from earlier gains and positioned above their 20-day moving average.

2026-08-10 23:51; UTC

Bristol-Myers Squibb Co shares are lower in after-market hours. The decline follows three consecutive sessions of gains amid shifting labor market sentiment.

2026-08-08 00:01; UTC

Bristol-Myers Squibb Co. shares are lower in after-market trading, continuing a decline since Friday's close despite being above the 20-day moving average.

2026-08-07 23:06; UTC

Bristol-Myers Squibb shares lower in after-market trading, despite maintaining a position above the 20-day moving average. No specific news was identified.

2026-08-06 23:26; UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, influenced by broader market trends and a stronger U.S. Dollar amid rising jobless claims.

2026-08-05 23:01; UTC

Bristol-Myers Squibb Co shares are lower in after-market hours. No specific news was identified to explain the movement.

2026-08-04 23:16; UTC

Bristol-Myers Squibb Co. shares gained in after-market trading, reflecting a modest uptick of 0.20% and remaining above their 20-day moving average.

2026-08-03 23:02; UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news identified to explain the movement. The stock remains above its 20-day moving average.

Akcijų palyginimas

Kainos pokytis

Bristol-Myers Squibb Co. Prognozė

Kainos tikslas

By TipRanks

4.26% į viršų

12 mėnesių prognozė

Vidutinis 66.833 USD  4.26%

Aukščiausias 80 USD

Žemiausias 40 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Bristol-Myers Squibb Co. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

20 ratings

8

Pirkti

11

Laikyti

1

Parduoti

Rinkos nuotaikos

By Acuity

73 / 339 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
help-icon Live chat